IVVD

Announcements

Nothing here yet

Daily updates

• Invivyd reported positive Phase 3 LIBERTY results showing VYD2311 met all primary and secondary safety and tolerability endpoints versus an mRNA COVID-19 vaccine.Sep 29, 2026

FDA designations

Nothing here yet

News

• Invivyd and the SPEAR Study Group initiate FLINTLOCK, a Phase 2 trial of monoclonal antibody VYD2311 for potential treatment of long COVID or post-vaccination syndromeOct 14, 2026
• Invivyd reports positive topline LIBERTY Phase 3 results showing VYD2311 was safe and well tolerated, with plans for regulatory submissionSep 29, 2026
• Invivyd advanced its REVOLUTION program and measles antibody candidate VMS063 for treatment and preventionApr 9, 2026
• Invivyd plans Phase 2 study of VYD2311 for Long COVID starting mid-2026Jan 20, 2026
• Invivyd announced selection of potential best-in-class RSV antibody candidate VBY329, targeting second half of 2026 IND readinessNov 24, 2025